FAK Inhibitors Market Growing Rapidly, Estimates DelveInsight | Verastem, GlaxoSmithKline, Merck Sharp & Dohme, Pfizer, InxMed are Expected to Contribute to Growth
The FAK inhibitors market is set for significant growth from 2019 to 2032, driven by emerging therapies with enhanced safety profiles and novel delivery methods for various cancers. Key companies, including Verastem, GlaxoSmithKline, Merck, and Immunocore (IMCR), are actively developing FAK inhibitors. Notable therapies under development include VS-6766 + defactinib and KIMMTRAK (tebentafusp), with several others awaiting approval. However, market expansion may be restricted by factors like therapy failures, high pricing, and access challenges. The report emphasizes the increasing focus on molecular therapies as traditional cytotoxic treatments have not yet cured cancer, highlighting the importance of FAK inhibitors for future oncology treatments.
- FAK inhibitors market projected to grow positively from 2019 to 2032.
- Key players like Verastem, GlaxoSmithKline, Merck, and Immunocore driving innovation.
- Development of promising therapies, including KIMMTRAK and VS-6766.
- Market growth may be hindered by therapy failures and discontinuation.
- High pricing and reimbursement issues could restrict patient access.
- Shortage of healthcare professionals may impact market dynamics.
The dynamics of the FAK inhibitor market is anticipated to change as companies across the globe are thoroughly working toward developing new FAK options with convenient RoA and better safety profile to treat a wide array of cancers. Key players, such as InxMed, Verastem, GlaxoSmithKline, Merck, and others, are involved in developing novel therapies for indications
Key Takeaways from the FAK Inhibitors Market Report
- DelveInsight analysis shows that the FAK inhibitors market is expected to grow positively due to several underline factors during the study period (2019–2032).
- Globally, leading FAK inhibitors companies such as Verastem, Inc.,
GlaxoSmithKline, Merck Sharp & Dohme LLC , Pfizer, InxMed, Amplia Therapeutics,Boehringer Ingelheim GmbH , Teva Pharmaceutical Industries,Immunocore , AstraZeneca,Genentech , and others are developing novel FAK inhibitors that can be available in the FAK inhibitors market in the coming years. - Some key FAK inhibitors include VS-6766 + defactinib, FAK Inhibitor GSK2256098, defactinib, VS-6063, Pembrolizumab, PF-04554878, IN10018, KIMMTRAK (tebentafusp), ZEJULA (niraparib), LYNPARZA (olaparib), AVASTIN (bevacizumab), and others.
- Several FAK inhibitors are awaiting approval, while some FAK inhibitors are in the advanced stages of development.
Discover which FAK inhibitors are expected to grab the major FAK inhibitors market share @ FAK Inhibitors Market Report
FAK Inhibitors Overview
Focal adhesion kinase (FAK) is a non-receptor tyrosine kinase that is overexpressed and activated in both adult and pediatric malignancies, where it plays critical roles in the regulation of pathogenesis and progression of the malignant phenotype. FAK operates in cancer in two ways: as a kinase activity in the cytoplasm, which is primarily dependent on integrin signaling, and as a scaffolding activity in the nucleus, which is accomplished through networking with various gene expressions. The FAK gene, also known as protein tyrosine kinase 2 (PTK2), is located on human chromosome 8q24.3 and encodes the FAK protein, which is found in many different types of cells and is mostly found in the plasma membrane and cytoplasm. FAK is classified into three domains: N-terminal FERM, core kinase, and C-terminal domains. The FAK FERM region is non-catalytic, and a similar FERM motif may be found in Janus kinase (JAK), another tyrosine kinase.
Learn more about FAK inhibitors for cancer therapy @ FAK Inhibitors
FAK Inhibitors Market Insights
Despite decades of cytotoxic chemotherapy experience, no drug or combination of agents has yet to cure cancer. Targeting molecular therapies to those molecules and pathways that promote cancer progression has become an increasingly appealing option as the biological underpinnings of carcinogenesis are better known. The FDA recently approved tebentafusp (Kimmtrak) for the treatment of selected individuals with uveal melanoma, as well as olaparib for the maintenance therapy of adult patients with deleterious or suspected detrimental germline BRCA-mutated (gBRCAm) metastatic pancreatic adenocarcinoma. The NICE has authorized Niraparib for women with advanced ovarian cancer.
The FDA approved tebentafusp, a bispecific fusion protein, in
To know more about FAK inhibitors, visit @ FAK Inhibitors Analysis
Key FAK Inhibitors Drugs and Companies
- VS-6766 + defactinib: Verastem, Inc.
- Defactinib: Verastem, Inc.
- FAK Inhibitor GSK2256098: GlaxoSmithKline
- VS-6063: Verastem, Inc.
- Pembrolizumab:
Merck Sharp & Dohme LLC - PF-04554878: Pfizer
- IN10018: InxMed
- KIMMTRAK (tebentafusp):
Immunocore - ZEJULA (niraparib): GlaxoSmithKline
- LYNPARZA (olaparib): AstraZeneca
- AVASTIN (bevacizumab):
Genentech
Learn more about the FDA-approved FAK inhibitors @ Approved FAK Inhibitors
FAK Inhibitors Market Dynamics
The dynamics of the FAK inhibitors market are expected to evolve as leading pharma and biotech companies around the world work hard to develop novel FAK choices with convenient RoA and a better safety profile to treat a wide range of malignancies. Furthermore, the FAK inhibitors pipeline is very robust; many potential therapies are being investigated for the treatment of various cancer, and it is safe to predict that the treatment space will significantly impact the oncology market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate is expected to drive the growth of the FAK inhibitors market in the 7MM.
However, several factors are impeding the growth of the FAK inhibitors market. Furthermore, the FAK inhibitors market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. Thus all these factors may cause a dip in the FAK inhibitors market growth in the coming year.
Report Metrics | Details |
Study Period | 2019–2032 |
Coverage | 7MM [ |
Base Year | 2019 |
Key FAK Inhibitors Companies | Verastem, Inc., |
Key FAK Inhibitors Therapies | VS-6766 + defactinib, FAK Inhibitor GSK2256098, defactinib, VS-6063, Pembrolizumab, PF-04554878, IN10018, KIMMTRAK (tebentafusp), ZEJULA (niraparib), LYNPARZA (olaparib), AVASTIN (bevacizumab), and others |
Scope of the FAK Inhibitors Market Report
- Therapeutic Assessment: Current Marketed and Emerging FAK Inhibitors
- FAK Inhibitors Market Dynamics: Attribute Analysis of Emerging FAK Inhibitors
- Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
- Unmet Needs, KOL's views, Analyst's views, FAK Inhibitors Market Access and Reimbursement
Discover more about FAK inhibitors in clinical development @ FAK Inhibitors in Clinical Trials
Table of Contents
1. | FAK Inhibitors Market Key Insights |
2. | FAK Inhibitors Market Report Introduction |
3. | FAK Inhibitors Market Overview at a Glance |
4. | FAK Inhibitors Market Executive Summary |
5. | Disease Background and Overview |
6. | FAK Inhibitors Marketed Drugs |
7. | FAK Inhibitors Emerging Drugs |
8. | Seven Major FAK Inhibitors Market Analysis |
9. | FAK Inhibitors Market Outlook |
10. | Potential of Current and Emerging Therapies |
11. | KOL Views |
12. | FAK Inhibitors Market Drivers |
13. | FAK Inhibitors Market Barriers |
14. | Unmet Needs |
15. | SWOT Analysis |
16. | Appendix |
17. | DelveInsight Capabilities |
18. | Disclaimer |
19. | About DelveInsight |
Related Reports
PD-1 Inhibitor Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key PD-1 inhibitor companies, including Genmab, RemeGen, Alphamab, OxSonics therapeutics, Light Chain Bioscience, ImmuneOnco Biopharma, Alpine Immune Sciences, Shanghai Henlius Biotech, Inc., Ocean Biomedical, Akeso Biopharma, Lyvgen Biopharma, Prestige Biopharma, ONO PHARMACEUTICAL CO., LTD., among others.
PD-1 and PD-L1 Inhibitors Competitive Landscape
PD-1 and PD-L1 Inhibitors Competitive Landscape – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key PD-1 and PD-L1 inhibitors companies, including Merck, Laekna Therapeutics,
JAK Inhibitors Competitive Landscape
JAK Inhibitors Competitive Landscape – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key JAK inhibitors companies, including Pfizer, Sierra Oncology, Theravance Biopharma, Dizal Pharmaceutical, Aclaris Therapeutics, Celon Pharma, Incyte Corporation, AbbVie, Galapagos, among others.
TIGIT Inhibitors Competitive Landscape
TIGIT Inhibitors Competitive Landscape – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key TIGIT inhibitors companies, including
Other Trending Oncology Reports
Glioblastoma Market | Intratumoral Cancer Therapies Market | Pancreatic Cancer Market | Metastatic Colorectal Cancer Market | Adeno-Associated Virus Vectors in Gene Therapy Market | Checkpoint Inhibitor Refractory Cancer Market | HER2+ Gastric Cancer Market | NSCLC - Market | Extensive-Stage Small Cell
Related Healthcare Blogs
Upcoming Oncological Drugs in 2023
Metastatic Castration-Sensitive Prostate Cancer Treatment Market
Checkpoint Inhibitor Refractory Cancer Market
Promising Oncolytic Virues Candidates in Pipeline
LAG 3: A Promising Next-Generation Cancer Immunotherapy
ENHERTU's Journey in Cancer Treatment and Management
Potential of PD-1 and PD-L1 Inhibitors in Cancer Management
Emerging Role of
Related Cases Studies
Related Healthcare Services
Healthcare Competitive Intelligence Services
Healthcare Asset Prioritization Services
About DelveInsight
DelveInsight is a leading
Connect with us on LinkedIn|Facebook|Twitter
Contact Us
Shruti Thakur
info@delveinsight.com
+1(919)321-6187
www.delveinsight.com
Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg
View original content:SOURCE
FAQ
What is driving the growth of the FAK inhibitors market?
Which companies are key players in the FAK inhibitors market?
What are some notable therapies in development for FAK inhibitors?
What challenges does the FAK inhibitors market face?
How is the FAK inhibitors market expected to evolve?
